[The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia].
A 47-year old woman patient suffering from chronic delayed sleep phase insomnia and low-dose benzodiazepine dependence was treated as an inpatient under close polygraphic control using DSIP (delta sleep inducing peptide) on an intensive-care basis for one week. This treatment resulted in advancing the main sleep phase by 5 hours, in an abrupt and complete withdrawal of flunitrazepam and restitution of a normal sleep profile. Actographic control during an after treatment week confirmed that the success was maintained.
D002940:Circadian Rhythm / Q000187:drug effects; D003701:Delta Sleep-Inducing Peptide / Q000627:therapeutic use*; D004569:Electroencephalography; D004576:Electromyography; D005260:Female; D005445:Flunitrazepam; D006801:Humans; D008875:Middle Aged; D007319:Sleep Initiation and Maintenance Disorders / Q000150:complications / Q000188:drug therapy*; D012895:Sleep, REM / Q000187:drug effects; D019966:Substance-Related Disorders / Q000150:complications*
D005445:Flunitrazepam; D003701:Delta Sleep-Inducing Peptide
Korrektur einer Insomnie mit Phasenverschiebung durch DSIP.